Jasper Hellweg
Stock Analyst at Argus Research
(2.77)
# 1,916
Out of 4,711 analysts
87
Total ratings
50%
Success rate
4.44%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $359.58 | +11.24% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $136.02 | +10.28% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $47.71 | +25.76% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $701.85 | +66.70% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $397.27 | +38.44% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $65.35 | +30.07% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $85.00 | +47.06% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $39.39 | +255.42% | 4 | Sep 13, 2023 | |
| BIIB Biogen | Maintains: Buy | $320 → $350 | $146.47 | +138.96% | 3 | May 11, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $175.58 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $164.84 | +21.33% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $22.09 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $197.27 | +47.01% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $133.67 | -25.19% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $228.61 | +29.04% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $8.10 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $153.10 | -11.82% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $29.50 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $25.75 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $258.43 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $114.64 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $56.94 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $303.62 | -48.95% | 3 | Nov 6, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $359.58
Upside: +11.24%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $136.02
Upside: +10.28%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $47.71
Upside: +25.76%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $701.85
Upside: +66.70%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $397.27
Upside: +38.44%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $65.35
Upside: +30.07%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $85.00
Upside: +47.06%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $39.39
Upside: +255.42%
Biogen
May 11, 2023
Maintains: Buy
Price Target: $320 → $350
Current: $146.47
Upside: +138.96%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $175.58
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $164.84
Upside: +21.33%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $22.09
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $197.27
Upside: +47.01%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $133.67
Upside: -25.19%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $228.61
Upside: +29.04%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $8.10
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $153.10
Upside: -11.82%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $29.50
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $25.75
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $258.43
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $114.64
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $56.94
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $303.62
Upside: -48.95%